FDA escalates warning letters over misleading drug advertising

1. Thousands of warning letters and 100 cease and desist orders mark the most aggressive FDA enforcement in years.
2. Weight-loss drug ads, including high-profile TV specials, were cited for inadequate disclosure of safety risks.

The FDA announced on September 9 that it had issued thousands of warning letters and about one hundred cease and desist orders aimed at pharmaceutical advertisements regulators deemed misleading. Campaigns for GLP-1 drugs such as Mounjaro and Zepbound were among those flagged, along with a widely broadcast Oprah Winfrey special that minimized safety disclosures. Until now, FDA enforcement had been limited, with no letters in 2024 and just one in 2023. Analysts note that this represents the strongest stance on drug advertising in more than a decade. Officials suggested that new formal advertising rules may follow, expanding oversight of both traditional and digital platforms. Direct-to-consumer advertising in the United States is a six billion dollar market, and the industry will likely face costly rewrites of promotional campaigns. For physicians, this shift could influence how patients frame questions during clinical visits, with less reliance on heavily curated ad messaging. The crackdown also addresses concerns about compounded formulations and online promotions that have been growing rapidly. Regulators appear determined to restore public trust in pharmaceutical communication by demanding more balanced messaging. Some companies may see reputational fallout if ads are viewed as intentionally misleading. Ultimately, the campaign signals a fundamental recalibration of the relationship between pharma, regulators, and the public.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.